1. Search Result
Search Result
Results for "

urokinase-type

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

12

Peptides

4

Recombinant Proteins

2

Isotope-Labeled Compounds

2

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0285
    Amiloride
    Maximum Cited Publications
    62 Publications Verification

    MK-870

    Sodium Channel TRP Channel Apoptosis Cardiovascular Disease Metabolic Disease
    Amiloride (MK-870) is an inhibitor of both epithelial sodium channel (ENaC ) and urokinase-type plasminogen activator receptor (uTPA ). Amiloride is a blocker of polycystin-2 (PC2; TRPP2 ) channel.
    Amiloride
  • HY-B0285A
    Amiloride hydrochloride
    Maximum Cited Publications
    62 Publications Verification

    MK-870 hydrochloride

    Sodium Channel TRP Channel Apoptosis Cardiovascular Disease Metabolic Disease
    Amiloride hydrochloride (MK-870 hydrochloride) is an inhibitor of both epithelial sodium channel (ENaC ) and urokinase-type plasminogen activator receptor (uTPA ). Amiloride hydrochloride is a blocker of polycystin-2 (PC2; TRPP2 ) channel.
    Amiloride hydrochloride
  • HY-111056
    UK122 TFA
    1 Publications Verification

    Ser/Thr Protease Cancer
    UK122 is a potent and selective urokinase-type plasminogen activator (uPA) inhibitor with an IC50 of 0.2 μM. UK122 shows no or little inhibition of tissue-type PA (tPA), plasmin, thrombin, and trypsin (all IC50>100 μM). UK122, 4-oxazolidinone analogue, is an anticancer agent and inhibits cancer cell migration and invasion .
    UK122 TFA
  • HY-B0285B
    Amiloride hydrochloride dihydrate
    Maximum Cited Publications
    62 Publications Verification

    MK-870 hydrochloride dihydrate

    Sodium Channel Apoptosis TRP Channel Cardiovascular Disease Metabolic Disease
    Amiloride hydrochloride dihydrate (MK-870 hydrochloride dihydrate) is an inhibitor of both epithelial sodium channel (ENaC ) and urokinase-type plasminogen activator receptor (uTPA ). Amiloride hydrochloride dihydrate is a blocker of polycystin-2 (PC2; TRPP2 ) channel.
    Amiloride hydrochloride dihydrate
  • HY-16511
    Upamostat
    1 Publications Verification

    WX-671

    PAI-1 Ser/Thr Protease Infection Cancer
    Upamostat (WX-671), a prodrug of WX-UK1, is an orally active serine protease inhibitor. Upamostat inhibits the urokinase-type plasminogen activator (uPA) system, blocking the plasminogen activation process mediated by it, thereby suppressing the invasion, migration and metastasis of tumor cells. Upamostat can be used in the research of metastatic breast cancer and locally advanced pancreatic cancer .
    Upamostat
  • HY-W018723
    4-Aminobenzamidine dihydrochloride
    1 Publications Verification

    p-Aminobenzamidine dihydrochloride

    Ser/Thr Protease PAI-1 Cardiovascular Disease Cancer
    4-Aminobenzamidine (p-Aminobenzamidine) dihydrochloride is a strong trypsin inhibitor. 4-Aminobenzamidine dihydrochloride acts as an orally active urokinase type plasminogen activator (uPA) inhibitor (Ki=82 μM). 4-Aminobenzamidine dihydrochloride can be used for cardiovascular diseases and anti-tumor study .
    4-Aminobenzamidine dihydrochloride
  • HY-101214

    PAI-1 Inflammation/Immunology
    UK-371804 is a urokinase-type plasminogen activator (uPA) inhibitor with a Ki of 10 nM.
    UK-371804
  • HY-P11446

    Transmembrane Glycoprotein Cancer
    AE105 is a 9-mer peptide probe targeting the urokinase-type plasminogen activator receptor (uPAR). AE105 binds tightly to the uPA-binding cavity of uPAR. AE105 can be used for the study of cancer .
    AE105
  • HY-100415

    WX-UK1; UKI-1C

    PAI-1 Ser/Thr Protease Cancer
    UKI-1 (WX-UK1) is a potent urokinase-type plasminogen activator (uPA) inhibitor with a Ki of 0.41 μM. UKI-1 is also a low molecular weight serine protease inhibitor. UKI-1 is a potent antimetastatic agent and inhibits the invasive capacity of carcinoma cells .
    UKI-1
  • HY-P5018

    Radionuclide-Drug Conjugates (RDCs) Ser/Thr Protease Cancer
    NOTA-AE105 is a PET ligand for the urokinase-type plasminogen activator receptor (uPAR). NOTA-AE105 can be radiolabeled with 64Cu and 68Ga. Images of 68Ga-NOTA-AE105 and 64Cu-NOTA-AE105 demonstrate high contrast and clear tumor delineation. NOTA-AE105 can be used in the synthesis of radionuclide-conjugated compounds (RDCs) .
    NOTA-AE105
  • HY-P1615

    Transmembrane Glycoprotein Cancer
    Cenupatide (UPARANT) is a Urokinase-type plasminogen activator receptor (uPAR) inhibitor. Cenupatide has anti-angiogenic and anti-inflammatory efficacy .
    Cenupatide
  • HY-B0285AR

    MK-870 hydrochloride (Standard)

    Reference Standards Sodium Channel TRP Channel Apoptosis Cardiovascular Disease Metabolic Disease
    Amiloride (hydrochloride) (Standard) is the analytical standard of Amiloride (hydrochloride). This product is intended for research and analytical applications. Amiloride hydrochloride (MK-870 hydrochloride) is an inhibitor of both epithelial sodium channel (ENaC ) and urokinase-type plasminogen activator receptor (uTPA ). Amiloride hydrochloride is a blocker of polycystin-2 (PC2; TRPP2 ) channel.
    Amiloride hydrochloride (Standard)
  • HY-P4254

    PAI-1 Ser/Thr Protease Others
    H-Gly-Glu-pNA is a chromogenic peptide substrate that can be widely used in enzymatic analysis, including trypsin and urokinase-type plasminogen activator (uPA) .
    H-Gly-Glu-pNA
  • HY-100939

    Sodium Channel Neurological Disease
    4-Chlorophenylguanidine hydrochloride is an urokinase-type plasminogen activator inhibitor. 4-Chlorophenylguanidine hydrochloride is a potent ASIC3 positive allosteric modulator and reverses the effects of ASIC3 desensitization. 4-Chlorophenylguanidine hydrochloride influences ASIC3 activity through directly activating the channel and increasing proton sensitivity. 4-Chlorophenylguanidine hydrochloride offers a chemical backbone for the design of new ASIC3 ligands to study ASIC3 in vivo .
    4-Chlorophenylguanidine hydrochloride
  • HY-P10877

    PAI-1 Cancer
    Bicyclic UK18 is a competitive inhibitor for human urokinase-type plasminogen activator (uPA) with a Ki of 53 nM .
    Bicyclic UK18
  • HY-B0285R

    MK-870 (Standard)

    Sodium Channel TRP Channel Apoptosis Reference Standards Cardiovascular Disease Metabolic Disease
    Amiloride (Standard) is the analytical standard of Amiloride. This product is intended for research and analytical applications. Amiloride (MK-870) is an inhibitor of both epithelial sodium channel (ENaC ) and urokinase-type plasminogen activator receptor (uTPA ). Amiloride is a blocker of polycystin-2 (PC2; TRPP2 ) channel.
    Amiloride (Standard)
  • HY-W013964

    (4-Iodophenyl)methanamine

    Biochemical Assay Reagents Others
    4-Iodobenzylamine ((4-Iodophenyl)methanamine) is a probe that can detect the binding patterns of serine proteases that are like trypsin, as well as urokinase-type plasminogen activator (uPA). 4-Iodobenzylamine is stable in aqueous solution .
    4-Iodobenzylamine
  • HY-111056A
    UK122 hydrochloride
    1 Publications Verification

    Ser/Thr Protease Cancer
    UK122 hydrochloride is a potent and selective urokinase-type plasminogen activator (uPA) inhibitor with an IC50 of 0.2 μM. UK122 hydrochloride shows no or little inhibition of tissue-type PA (tPA), plasmin, thrombin, and trypsin (all IC50s > 100 μM). UK122 hydrochloride, a 4-oxazolidinone analogue, is an anticancer agent and inhibits cancer cell migration and invasion .
    UK122 hydrochloride
  • HY-P11413

    Ser/Thr Protease Cardiovascular Disease
    PAI-1 is a plasminogen activator inhibitor. PAI-1 is a member of the Ser Protease inhibitor superfamily with antiprotease activity. PAI-1 is the main physiological inhibitor of tissue-type (tPA) and urokinase-type (uPA) plasminogen activators (PAs) .
    PAI-1
  • HY-P11446A

    Transmembrane Glycoprotein Cancer
    AE105 TFA is a 9-mer peptide probe targeting the urokinase-type plasminogen activator receptor (uPAR). AE105 TFA binds tightly to the uPA-binding cavity of uPAR. AE105 TFA can be used for the study of cancer .
    AE105 TFA
  • HY-B0285AS

    MK-870-15N3 hydrochloride

    Apoptosis TRP Channel Sodium Channel Metabolic Disease
    Amiloride- 15N3 (hydrochloride) is the 15N labeled Amiloride hydrochloride . Amiloride hydrochloride (MK-870 hydrochloride) is an inhibitor of both epithelial sodium channel (ENaC ) and urokinase-type plasminogen activator receptor (uTPA ). Amiloride hydrochloride is a blocker of polycystin-2 (PC2;TRPP2 ) channel.
    Amiloride-15N3 hydrochloride
  • HY-W104868

    Biochemical Assay Reagents Ser/Thr Protease Others
    4-Iodobenzylamine hydrochloride ((4-Iodophenyl)methanamine hydrochloride) is a probe that can detect the binding patterns of serine proteases that are like trypsin, as well as urokinase-type plasminogen activator (uPA) .
    4-Iodobenzylamine hydrochloride
  • HY-101214A

    PAI-1 Others
    UK-371804 hydrochloride (compound 24) is a urokinase-type plasminogen activator (uPA) inhibitor with a Ki of 10 nM .
    UK-371804 hydrochloride
  • HY-137495

    PAI-1 Ser/Thr Protease Cancer
    GGACK (H-Glu-Gly-Arg-CMK) is an irreversible substrate-like serine protease urokinase-type plasminogen activator (uPA) inhibitor .
    GGACK
  • HY-137495A

    PAI-1 Ser/Thr Protease Cancer
    GGACK (H-Glu-Gly-Arg-CMK) hydrochloride is an irreversible substrate-like serine protease urokinase-type plasminogen activator (uPA) inhibitor .
    GGACK hydrochloride
  • HY-135715

    PAI-1 Others
    (E)-UK122 TFA is the isomer of UK122 TFA. UK122 is a potent and selective urokinase-type plasminogen activator (uPA) inhibitor with an IC50 of 0.2 μM .
    (E)-UK122 TFA
  • HY-P10878

    PAI-1 Cancer
    UK140 is the inhibitor for urokinase-type plasminogen activator (uPA) with Ki of 0.20 µM and 2.79 µM for huPA anf muPA. UK140 can be used in metastasis-related research .
    UK140
  • HY-B0285BR

    MK-870 hydrochloride dihydrate (Standard)

    Reference Standards Sodium Channel Apoptosis TRP Channel Cardiovascular Disease Metabolic Disease
    Amiloride hydrochloride dihydrate (Standard) is the analytical standard of Amiloride hydrochloride dihydrate. This product is intended for research and analytical applications. Amiloride hydrochloride dihydrate (MK-870 hydrochloride dihydrate) is an inhibitor of both epithelial sodium channel (ENaC ) and urokinase-type plasminogen activator receptor (uTPA ). Amiloride hydrochloride dihydrate is a blocker of polycystin-2 (PC2; TRPP2 ) channel.
    Amiloride hydrochloride dihydrate (Standard)
  • HY-B0285S

    MK-870-15N3

    Isotope-Labeled Compounds Apoptosis Sodium Channel TRP Channel Cardiovascular Disease Metabolic Disease
    Amiloride- 15N3 (MK-870- 15N3) is 15N labeled Amiloride. Amiloride (MK-870) is an inhibitor of both epithelial sodium channel (ENaC ) and urokinase-type plasminogen activator receptor (uTPA ). Amiloride is a blocker of polycystin-2 (PC2; TRPP2 ) channel.
    Amiloride-15N3
  • HY-123685

    PAI-1 Cancer
    UCD74A (compound 18) hydrochloride is a 5-substituted amiloride analog and urokinase-type plasminogen activator (uPA) inhibitor with an IC50 of 110 μM.UCD74A (hydrochloride) modulates plasminogen activation cascades linked to extracellular matrix remodeling.UCD74A (hydrochloride) can be used for the research of tumor metastasis .
    UCD74A hydrochloride
  • HY-129690

    Ser/Thr Protease Inflammation/Immunology
    UK-356202 is a urokinase-type plasminogen activator (uPA) with a Ki value of 0.037 μM. UK-356202 can be used in research related to the topical treatment of chronic ulcerous wounds .
    UK-356202
  • HY-182450

    Ser/Thr Protease Cancer
    WX-293 is a highly selective urokinase-type plasminogen activator (uPA) inhibitor with a Ki value of 2.4 μM. WX-293 abolishes hypoxia-induced keratinocyte migration and in vitro wound closure. WX-293 can be used in research on hypoxia-mediated skin wounds and solid malignant tumors .
    WX-293
  • HY-16512

    WX-671 hydrogen sulfate

    PAI-1 Ser/Thr Protease Cancer
    Upamostat (WX-671) hydrogen sulfate, a prodrug of WX-UK1 (HY-100415), is an orally active serine protease inhibitor. Upamostat hydrogen sulfate inhibits the urokinase-type plasminogen activator (uPA) system, blocking the plasminogen activation process mediated by it, thereby suppressing the invasion, migration and metastasis of tumor cells. Upamostat hydrogen sulfate can be used in the research of metastatic breast cancer and locally advanced pancreatic cancer .
    Upamostat hydrogen sulfate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: